Federal Pre-emption Defense Under Fire In Draft House Bills
This article was originally published in The Tan Sheet
Executive Summary
A one-sentence provision tucked into draft House legislation renewing FDA's drug user fee program seeks to weaken manufacturers' ability to use FDA approval as a defense in state product liability lawsuits
You may also be interested in...
Phantom Stopgap PDUFA Renewal Might Prompt Faster FDARA Action
A proposal apparently circulated by House Democratic leaders to renew user fee programs for three months while negotiations on FDA reform legislation continue is "not an option," Sen. Michael Enzi, R-Wyo., ranking member of the Health, Education, Labor and Pensions Committee, has declared
Phantom Stopgap PDUFA Renewal Might Prompt Faster FDARA Action
A proposal apparently circulated by House Democratic leaders to renew user fee programs for three months while negotiations on FDA reform legislation continue is "not an option," Sen. Michael Enzi, R-Wyo., ranking member of the Health, Education, Labor and Pensions Committee, has declared
Phantom Stopgap PDUFA Renewal Might Prompt Faster FDARA Action
A proposal apparently circulated by House Democratic leaders to renew user fee programs for three months while negotiations on FDA reform legislation continue is "not an option," Sen. Michael Enzi, R-Wyo., ranking member of the Health, Education, Labor and Pensions Committee, has declared